Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 09, 2022

Front-Line Hyper-CVAD–Based Regimens, Including Hyper-CVAD Plus Ponatinib, in Patients With ALL

Leukemia Research

 

Additional Info

Disclosure statements are available on the authors' profiles:

Leukemia Research
Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center
Leuk. Res 2022 Aug 01;119(xx)106885, T Othman, BN Moskoff, G Ho, et al

Further Reading